[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631343":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":295,"collaborators":25,"id":297,"slug":298,"hasResults":299,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":25,"eligibilityCriteria":303,"healthyVolunteers":299,"sex":304,"minAge":305,"maxAge":306,"enrollmentInfo":307,"targetDuration":25,"studyType":310,"phases":311,"briefSummary":313,"conditions":314,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},{"fullName":5,"class":6},"HB BioTech, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HB-1","EXPERIMENTAL","HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.",[13],"Drug: HB-1",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matched Placebo will be supplied as a tablet.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","HB-1 will be supplied as a dual active pharmaceutical ingredient tablet. The two HB-1 doses for this study include 64\u002F192 and 86\u002F258 telmisartan\u002Fverapamil extended release, using unique bi-layer tablets.\n\nAll subjects randomized to receive HB-1 will begin with the 64\u002F192mg dose taken as one tablet once per day.\n\nAt each monthly visit, treatment tolerance and response will be adjudicated using objective, dose-escalation criteria. At both Week 4 and Week 8, all subjects will be evaluated for dose escalation. Subjects who are demonstrating a reduction of 50% or more in CAPS-5 total score will remain in treatment with HB-1 (or Placebo) at same dose. Subjects with less than a 50% reduction in CAPS-5, who have experienced no treatment-emergent Grade 3 or higher adverse event related to study drug since the prior visit, will be dose-escalated to the 86\u002F258mg telmisartan\u002Fverapamil extended dose. After escalation, subjects will remain on higher dose throughout the remainder of the study.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Matching Placebo will be dispensed to analogous subjects in Placebo group.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Karen Smith","CONTACT","+1-650-722-9813","karen.smith@hbbio.com",{"name":36,"role":32,"phone":25,"phoneExt":37,"email":38},"Alon Seifan","+1-786-620-320","alon.seifan@hbbio.com",[40,62,79,95,111,128,147,163,179,195,215,234,250,266,278],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Paratus Clinical Research Canberra","RECRUITING","Bruce","Australian Capital Territory","2617","Australia","AU",{"type":49,"coordinates":50},"Point",[51,52],149.09083,-35.24405,{"lat":52,"lon":51},[55,59],{"name":56,"role":32,"phone":57,"phoneExt":25,"email":58},"Jessica Daley","+61 1300 742 326","jessica.daley@paratusclinical.com",{"name":60,"role":61,"phone":25,"phoneExt":25,"email":25},"Dr Amber Leah","PRINCIPAL_INVESTIGATOR",{"facility":63,"status":42,"city":64,"state":65,"zip":66,"country":46,"countryCode":47,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Novatrials","Charlestown","New South Wales","2290",{"type":49,"coordinates":68},[69,70],151.69318,-32.96828,{"lat":70,"lon":69},[73,77],{"name":74,"role":32,"phone":75,"phoneExt":25,"email":76},"Karen Brenan","+61 2 4089 3744","karen@novatrials.com.au",{"name":78,"role":61,"phone":25,"phoneExt":25,"email":25},"Dr Vidushi Khatri",{"facility":80,"status":42,"city":81,"state":65,"zip":82,"country":46,"countryCode":47,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"East Sydney Doctors","Darlinghurst","2010",{"type":49,"coordinates":84},[85,86],151.21925,-33.87939,{"lat":86,"lon":85},[89,93],{"name":90,"role":32,"phone":91,"phoneExt":25,"email":92},"Chloe Williamson","+61 2 9332 2531","trials@eastsydneydoctors.com.au",{"name":94,"role":61,"phone":25,"phoneExt":25,"email":25},"Dr David Baker",{"facility":96,"status":42,"city":97,"state":65,"zip":98,"country":46,"countryCode":47,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Innovate Clinical Research","Waitara","2077",{"type":49,"coordinates":100},[101,102],151.1033,-33.71092,{"lat":102,"lon":101},[105,109],{"name":106,"role":32,"phone":107,"phoneExt":25,"email":108},"Regina Cruz","+61 2 9159 3838","rcruz@innovateclinical.com.au",{"name":110,"role":61,"phone":25,"phoneExt":25,"email":25},"Rachel Graham",{"facility":112,"status":113,"city":114,"state":65,"zip":115,"country":46,"countryCode":47,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"WSLHD Mental Health Services, Westmead Hospital","NOT_YET_RECRUITING","Westmead","2145",{"type":49,"coordinates":117},[118,119],150.98768,-33.80383,{"lat":119,"lon":118},[122,126],{"name":123,"role":32,"phone":124,"phoneExt":25,"email":125},"Taiba Shafaie-Eshaq","+61 2 8890 6688","taiba.shafaieeshaq@health.nsw.gov.au",{"name":127,"role":61,"phone":25,"phoneExt":25,"email":25},"Prof. Valsios Brakoulias",{"facility":129,"status":113,"city":130,"state":131,"zip":132,"country":46,"countryCode":47,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Paratus Clinical Research Brisbane","Herston","Queensland","4006",{"type":49,"coordinates":134},[135,136],153.01852,-27.44453,{"lat":136,"lon":135},[139,142,145],{"name":140,"role":32,"phone":57,"phoneExt":25,"email":141},"Steve Turner","steve.turner@paratusclinical.com",{"name":143,"role":32,"phone":25,"phoneExt":25,"email":144},"Lauren Marshall","lauren.marshall@paratusclinical.com",{"name":146,"role":61,"phone":25,"phoneExt":25,"email":25},"Pi Lip Seet",{"facility":148,"status":113,"city":149,"state":131,"zip":150,"country":46,"countryCode":47,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Mackay Hospital and Health Service","Mackay","4740",{"type":49,"coordinates":152},[153,154],149.16554,-21.15345,{"lat":154,"lon":153},[157,161],{"name":158,"role":32,"phone":159,"phoneExt":25,"email":160},"Joshua Paterson","+61 7 4885 6000","Mackay-Clinical-Trials@health.qld.gov.au",{"name":162,"role":61,"phone":25,"phoneExt":25,"email":25},"Alok Rana",{"facility":164,"status":113,"city":165,"state":131,"zip":166,"country":46,"countryCode":47,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"University of the Sunshine Coast Clinical Trials, Morayfield","Morayfield","4506",{"type":49,"coordinates":168},[169,170],152.94907,-27.10876,{"lat":170,"lon":169},[173,177],{"name":174,"role":32,"phone":175,"phoneExt":25,"email":176},"Alistair Mallard","+61 7 5409 8644","amallard@usc.edu.au",{"name":178,"role":61,"phone":25,"phoneExt":25,"email":25},"Chris Moller",{"facility":180,"status":113,"city":181,"state":131,"zip":182,"country":46,"countryCode":47,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"University of the Sunshine Coast Clinical Trials, Sippy Downs","Sippy Downs","4556",{"type":49,"coordinates":184},[185,186],153.05475,-26.71793,{"lat":186,"lon":185},[189,192,193],{"name":190,"role":32,"phone":175,"phoneExt":25,"email":191},"Ryan Stewart","rstewart2@usc.edu.au",{"name":25,"role":32,"phone":175,"phoneExt":25,"email":176},{"name":194,"role":61,"phone":25,"phoneExt":25,"email":25},"Amanda Thomson",{"facility":196,"status":42,"city":197,"state":198,"zip":199,"country":46,"countryCode":47,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"South Australian Health and Medical Research Institute","Adelaide","South Australia","5000",{"type":49,"coordinates":201},[202,203],138.59863,-34.92866,{"lat":203,"lon":202},[206,209,213],{"name":207,"role":32,"phone":25,"phoneExt":25,"email":208},"Gemma Barker","gemma.barker@sahmri.com.au",{"name":210,"role":32,"phone":211,"phoneExt":25,"email":212},"Emma Heath","+61 8 8128 4358","emma.heath@sahmri.com",{"name":214,"role":61,"phone":25,"phoneExt":25,"email":25},"Frances Adams",{"facility":216,"status":113,"city":217,"state":218,"zip":219,"country":46,"countryCode":47,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"NeuroCentrix","Carlton","Victoria","3053",{"type":49,"coordinates":221},[222,223],144.96667,-37.8,{"lat":223,"lon":222},[226,230,233],{"name":227,"role":32,"phone":228,"phoneExt":25,"email":229},"Nicola Valcanis","+61 3 9546 0009","nicola@neurocentrix.com.au",{"name":231,"role":32,"phone":25,"phoneExt":25,"email":232},"David Barton","david@neurocentrix.com.au",{"name":231,"role":61,"phone":25,"phoneExt":25,"email":25},{"facility":235,"status":42,"city":236,"state":218,"zip":237,"country":46,"countryCode":47,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"Peninsula Therapeutic and Research Group","Frankston","3199",{"type":49,"coordinates":239},[240,241],145.12291,-38.14458,{"lat":241,"lon":240},[244,248],{"name":245,"role":32,"phone":246,"phoneExt":25,"email":247},"Xenia Jung","+61 3 9770 1579","xjung@ptrg.com.au",{"name":249,"role":61,"phone":25,"phoneExt":25,"email":25},"Jennifer Grunfeld",{"facility":251,"status":113,"city":252,"state":218,"zip":253,"country":46,"countryCode":47,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"Monash Alfred Psychiatry Research Centre","Melbourne","3004",{"type":49,"coordinates":255},[256,257],144.96332,-37.814,{"lat":257,"lon":256},[260,264],{"name":261,"role":32,"phone":262,"phoneExt":25,"email":263},"Marta Malicka","+61 3 9076 6924","marta.malicka@monash.edu",{"name":265,"role":61,"phone":25,"phoneExt":25,"email":25},"Dr Rebecca Ho",{"facility":267,"status":42,"city":252,"state":218,"zip":253,"country":46,"countryCode":47,"cosmosGeoPoint":268,"geoPoint":270,"contacts":271},"Ramsay Clinic Albert Road",{"type":49,"coordinates":269},[256,257],{"lat":257,"lon":256},[272,276],{"name":273,"role":32,"phone":274,"phoneExt":25,"email":275},"Melanie Hurley","+61 3 9279 3569","research.arc@ramsayhealth.com.au",{"name":277,"role":61,"phone":25,"phoneExt":25,"email":25},"Malcolm Hopwood",{"facility":279,"status":42,"city":280,"state":218,"zip":281,"country":46,"countryCode":47,"cosmosGeoPoint":282,"geoPoint":286,"contacts":287},"Paratus Clinical Research Melbourne","Northcote","3070",{"type":49,"coordinates":283},[284,285],145,-37.76667,{"lat":285,"lon":284},[288,291,293],{"name":289,"role":32,"phone":57,"phoneExt":25,"email":290},"Jesse Alderson","recruitment@paratusclinical.com",{"name":292,"role":32,"phone":25,"phoneExt":25,"email":25},"A\u002FProf Bernadette Fitzgibbon",{"name":294,"role":61,"phone":25,"phoneExt":25,"email":25},"Dr Kianoosh Noori Samie",{"type":296,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100631343","phase-2-safety-and-efficacy-of-hb-1-for-post-traumatic-stress-disorder-100631343",false,"NCT07499440","Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder","Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Male or female aged 18 to 65 years old, inclusive, at the time of informed consent.\n* Meets DSM-V Criteria for PTSD.\n* Minimum CAPS-5 score of at least 26 (based on the optimal diagnostic correspondence in the definitive CAPS-5 psychometric validation study).\n* Clinically stable on current medication and\u002For therapy regimen for at least 2 months, as determined by Investigator.\n* Willing to remain on current doses of other psychiatric medications throughout the length of the trial.\n* Willing and able to safely stop any medications that are contraindicated to be taken together with HB-1, as determined by Investigator.\n* Fluent in English.\n* Willing to take HB-1.\n* Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.\n* Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or agree to commit to use acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study. Investigator shall use discretion and familiarity with subject's preferred and usual lifestyle to understand if reporting of abstinence may be trusted to achieve 100% effectiveness. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.\n* Female subjects who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening within 7 days of dosing with study treatment.\n\nExclusion Criteria:\n\n* Any ongoing concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.\n* Ongoing treatment with benzodiazepines (e.g. alprazolam, diazepam, clonazepam, lorazepam) or opiates (e.g., codeine, morphine) as assessed by clinical interview and urine toxicology testing.\n* Ongoing treatment with any medication that has a clinically significant drug-drug interaction with either telmisartan or verapamil, per the verapamil SR and telmisartan FDA labels and per standard drug interaction compendia. These include but are not limited to: Inhibitors or inducers of cytochrome P450 (CYP)3A4 (including certain β-hydroxy β-methylglutaryl-CoA \\[HMG-CoA\\] reductase inhibitors), Ivabradine, Antihypertensive Agents (including Beta Blockers), Antiarrhythmic Agents, Lithium, Carbamazepine, Rifampin, Phenobarbital, cyclosporin, theophylline, Inhalation Anesthetics, Neuromuscular Blocking Agents, Telithromycin, mTOR inhibitors as well as strong P-glycoprotein inhibitors (e.g., macrolides, ritonavir, itraconazole, ketoconazole, cyclosporin, ritonavir, and ivermectin).\n* Diagnosis of Severe Substance Use Disorder, Obsessive-Compulsive Disorder (OCD), Bipolar I, Bipolar II disorder, or Psychotic disorder (per SCID-V) or Borderline Personality Disorder (per Short-Bord).\n* Active suicidal ideation and behavior (Columbia-Suicide Severity Rating Scale \\[C-SSRS\\] score ≥ 4 at Screening, or who has made a serious suicide attempt in the last 3 months).\n* Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to: severe uncontrolled hypertension, hypotension (below 90\u002F60 mmHg); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).\n* Any clinically significant electrocardiogram (ECG) abnormalities at screening.\n* Inadequate hepatic function defined as total bilirubin \\> 1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\> 3 × the ULN range of each institution.\n* Inadequate renal function defined as serum creatinine \\> 1.5 × the ULN range of each institution and\u002For estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin.\n* Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.\n* Already on treatment with either telmisartan or verapamil or both.\n* Documented contraindication to taking telmisartan or verapamil: (eg, prior drug allergy, Duchenne's muscular dystrophy, myasthenia gravis).\n* Pregnant or breastfeeding.\n* Participation in another current clinical trial or prior trial within the last three months.\n* Urinalysis evidence of exposure to substances that may interfere with HB-1 testing (per investigator discretion).","ALL","18 Years","65 Years",{"count":308,"type":309},200,"ESTIMATED","INTERVENTIONAL",[312],"PHASE2","The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).",[315,316],"PTSD","Mental Illness","2026-06-03",{"date":319,"type":320},"2026-06-04","ACTUAL",{"date":322,"type":309},"2026-06",{"date":324,"type":309},"2027-10",{"name":5,"class":6},15]